Thursday, December 19, 2013
Publication and contact
mouse model of autism
Mice with a heterozygous,
autism-linked Pten deletion could be used to screen therapeutics for
autism spectrum disorder. Brain slices from heterozygous Pten
knockouts had higher levels of potassium
channel KCa2.2 (Kcnn2)
and had lower excitatory response after electrical and pharmacological
stimulation than brain slices from wild-type controls. Next steps could
include testing the effect of KCNN2 antagonists on neuronal excitability.
Acesion Pharma ApS has
inhibitors of KCNN2 and other small conductance calcium-activated potassium
channels in discovery stage development to treat atrial fibrillation (AF).
Published online Dec. 19, 2013
Patent and licensing status
Garcia-Junco-Clemente, P. et
Proc. Natl. Acad. Sci. USA;
published online Oct. 21, 2013;
Contact: Peyman Golshani, University of California, Los Angeles
David Geffen School of Medicine, Los Angeles, Calif.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]